Dacomitinib/Dacomitinib 804 enters the brain

Dacomitinib/Dacomitinib (Dacomitinib) is not directly called 804, but in some contexts or specific groups, 804 may be some informal name or code name for dacomitinib. The generic name of dacomitinib is dacomitinib tablets, and the trade name is Duozerun/VIZIMPRO. It is a tyrosine kinase inhibitor mainly used to treat non-small cell lung cancer. It is a second-generation, irreversible EGFR tyrosine kinase inhibitor developed by Pfizer of the United States. Therefore, if in a formal setting or when precise expression is required, it is recommended to use the generic or trade name of dacomitinib to avoid confusion.

In theARCHER1050 study, dacomitinib showed higher progression-free survival (PFS) and overall survival compared with gefitinib in patients with advanced non-small cell lung cancer carrying epidermal growth factor receptor (EGFR) mutations. However, because the study did not include patients with brain metastases, the efficacy of dacomitinib in patients with brain metastases has not yet been established. There have also been studies on patients with brain metastases. All patients had unirradiated brain metastases with a diameter≥5 mm. The primary endpoint was confirmed intracranial objective response rate (iORR).

The results showed that patients had exon 19 deletion (46.7%) and exon 21 L858R mutation (55.3%). ConfirmediORR was 96.7%, and intracranial complete response rate was 63.3%. Median intracranial PFS (iPFS) was not reached, with iPFS rates at 12 and 18 months of 78.6% and 70.4%, respectively. In a competing risk analysis, the cumulative incidence of intracranial progression at 12 months was 16.7%. Regarding the overall efficacy in intracranial and extracranial lesions, the overall ORR was 96.7% and the median PFS was 17.5 months. Therefore dacomitinib has significant intracranial efficacy in patients with EGFR mutant non-small cell lung cancer with brain metastases.